Registry for adults with severe asthma receiving biologic treatments in Taiwan
Official title: Taiwan Severe Asthma Biologic Registry
Run by Taichung Veterans General Hospital · NCT06456450 · Data updated 2026-11-12
This study is tracking adults with severe asthma in Taiwan who are using biologic treatments to see how well they work and what factors might help choose the best options.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Taichung Veterans General Hospital Academic / other |
| Drugs / interventions | omalizumab, mepolizumab, benralizumab, dupilzumab, Tezepelumab |
| Locations | 1 site (Taichung) |
| Status | Recruiting |
| Started | November 11, 2023 |
| Main results expected | February 28, 2043 |
| Study ends | February 28, 2043 |
| Registry record updated | May 19, 2026 |
| Trial ID | NCT06456450 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 18 years old with severe asthma who have started biologic treatment after January 1, 2020.
✕Probably not a fit
Patients with a history of biologic treatment prior to January 1, 2020, or those with significant comorbid pulmonary diseases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to register adult patients with severe asthma who are receiving biologic treatments in Taiwan. It will evaluate the real-world effectiveness of these treatments, the impact of initiating or switching biologics, and identify potential factors that predict the best treatment options. The study will also assess risk factors associated with poor asthma control and compare the clinical remission rates among different biologics. Participants will include those treated with omalizumab, mepolizumab, benralizumab, dupilumab, or Tezep.
Why it matters
Potential benefit: If successful, this study could provide insights into the most effective biologic treatments for severe asthma, leading to improved patient outcomes.
How similar studies have gone: Other studies have shown success in evaluating the effectiveness of biologics for severe asthma, making this approach both relevant and supported by prior findings.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Provision of informed consent prior to any study specific procedures. * Patient should be reviewed as well as confirmed by the National Health Insurance Administration (NHIA) or by the study board member as a Severe Asthma case. * Female and male aged over 18 years old. * Patients who are treated either with omalizumab, mepolizumab, or benralizumab after January 1, 2020. Exclusion Criteria: * Lack of informed consent for participation. * History of Biologic usage before January 1, 2020, should be ruled out. * The washout period should be at least 12 months. In other words, the enrolled patients should have no experience in receiving a biological treatment or in participating relative clinical trial before his/her biologic initiation. * Comorbid pulmonary diseases (e.g.: Chronic Obstructive Pulmonary Disease, Bronchiectasis, Pulmonary Fibrosis, etc.) or risk factors (e.g.: smoking or environmental exposure, etc..) that could be associated with pulmonary or systemic diseases, other than Asthma.
Where it's running
-
Taichung Veterans General Hospital
Taichung, Taiwan Recruiting
Study contacts
- Study coordinator: Pin-Kuei Fu, MD.,PhD.
- Email: yetquen@gmail.com
- Phone: 886-4-23592525
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using stem cells from umbilical cords to treat lung diseases
This study is testing if a single infusion of stem cells from umbilical cords can help people with lung diseases like asthma and COPD feel better and improve their health over time.
-
Chronic Respiratory Disease Participant Engagement
This study tests whether adults with long-term lung conditions can get comfortable with a clinical trials unit and research team before joining future trials.
-
HB0056 in adults with moderate to severe asthma
This study tests HB0056 versus a placebo to see if it helps adults with moderate to severe asthma reduce rescue inhaler use and improve symptoms.
-
Tilrekimig (PF-07275315) for Severe Asthma: Aimed at Adults with Frequent Exacerbations
This study tests whether tilrekimig helps people with severe asthma who have had multiple flare-ups in the past year, by comparing it to a placebo given every four weeks.
-
Inhaled CHF10136 safety and pharmacokinetics in healthy adults and adults with asthma
This first-in-human study tests inhaled CHF10136 to see if it is safe and well tolerated, how it behaves in the body, and how it affects adults with asthma compared with placebo.
-
Biologics for Type 2 Inflammation in Asthma and COPD in Real World
This real-world study tests whether six biologic drugs can reduce flare-ups and improve symptoms in adults with asthma or COPD treated in routine care in China.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.